Background Background Concern is widespread
Concern is widespread about potential sponsorship influence on about potential sponsorship influence on research, especiallyin pharmacoeconomic research, especiallyin pharmacoeconomic studies.Quantitative analysis of possible studies.Quantitative analysis of possible bias in such studies is limited. bias in such studies is limited.
Aims Aims To determine whether there is an
To determine whether there is an association between sponsorship and association between sponsorship and quantitative outcomes in pharmacoquantitative outcomes in pharmacoeconomic studies of antidepressants. economic studies of antidepressants.
Method Method Using all identifiable articles
Using all identifiable articles with original comparative quantitative with original comparative quantitative cost or cost-effectiveness outcomes for cost or cost-effectiveness outcomes for antidepressants, we performed antidepressants, we performed contingency table analyses of study contingency table analyses of study sponsorship and design sponsorship and design v.
v. study outcome. study outcome.
Results
Results Studies sponsored by selective Studies sponsored by selective serotonin reuptake inhibitor (SSRI) serotonin reuptake inhibitor (SSRI) manufacturers favoured SSRIs over manufacturers favoured SSRIs over tricyclic antidepressants more than nontricyclic antidepressants more than nonindustry-sponsored studies. Studies industry-sponsored studies. Studies sponsored by manufacturers of newer sponsored by manufacturers of newer antidepressants favoured these drugs antidepressants favoured these drugs more than did non-industry-sponsored more than did non-industry-sponsored studies. Among industry-sponsored studies. Among industry-sponsored studies, modelling studies favoured the studies, modelling studies favoured the sponsor's drug more than did sponsor's drug more than did administrative studies.Industryadministrative studies.Industrysponsored modelling studies were more sponsored modelling studies were more favourable to industry than were nonfavourable to industry than were nonindustry-sponsored ones. industry-sponsored ones.
Conclusions Conclusions Pharmacoeconomic
Pharmacoeconomic studies of antidepressants reveal clear studies of antidepressants reveal clear associations of study sponsorship with associations of study sponsorship with quantitative outcome. quantitative outcome.
Declaration of interest Declaration of interest Range of
Range of industry and non-industry funding industry and non-industry funding received, detailed in Acknowledgements. received, detailed in Acknowledgements.
Long-standing concern exists about the Long-standing concern exists about the potential influence of financial interests on potential influence of financial interests on medical decision-making (e.g. Hillman medical decision-making (e.g. Hillman et al et al, 1990; Rennie & Flanagin, 1992) . , 1990; Rennie & Flanagin, 1992) . Especially vigorous discussion has centred Especially vigorous discussion has centred on the conduct and reporting of pharmacoon the conduct and reporting of pharmacoeconomic research (e.g. Hillman economic research (e.g. Hillman et al et al, 1991; , 1991; Udrarhelyi Udrarhelyi et al et al, 1992; Gulati & Bitran, , 1992; Gulati & Bitran, 1995; Siegel 1995; Siegel et al et al, 1996; Neumann, 1998; , 1996; Neumann, 1998; Hill Hill et al et al, 2000; Jones & Cockrum, 2000; , 2000; Jones & Cockrum, 2000; Neumann Neumann et al et al, 2000 , 2000b . However, there ). However, there has been little quantitative study of potenhas been little quantitative study of potential bias in pharmacoeconomic research tial bias in pharmacoeconomic research throughout medicine. Reported studies have throughout medicine. Reported studies have reached mixed conclusions (e.g. Sacristan reached mixed conclusions (e.g. Sacristan et et al al, 1997; Azimi & Welch, 1998; Friedberg , 1997; Azimi & Welch, 1998; Friedberg et al et al, 1999; Neumann , 1999; Neumann et al et al, 2000 Neumann et al et al, , 2000a , perhaps ), perhaps in part because with one exception in part because with one exception (Friedberg (Friedberg et al et al, 1999) they investigated , 1999) they investigated several drugs and in some cases included several drugs and in some cases included medical devices. We are unaware of any medical devices. We are unaware of any study focused on psychiatric medication. study focused on psychiatric medication.
We studied associations between We studied associations between sponsorship and study design with quantitasponsorship and study design with quantitative outcome in pharmacoeconomic studies tive outcome in pharmacoeconomic studies by examining the test case of antiby examining the test case of antidepressants. We asked the following depressants. We asked the following primary questions. First, is there an associaprimary questions. First, is there an association between industry tion between industry v v. non-industry . non-industry sponsorship of studies and quantitative sponsorship of studies and quantitative conclusions? Second, among industryconclusions? Second, among industrysponsored studies and between industrysponsored studies and between industrysponsored sponsored v. v. non-industry-sponsored non-industry-sponsored studies, is there an association between studies, is there an association between study design and quantitative conclusions? study design and quantitative conclusions?
METHOD METHOD
We chose antidepressants licensed in the We chose antidepressants licensed in the UK or the USA as our test case because of UK or the USA as our test case because of their large market share and the number of their large market share and the number of pharmacoeconomic studies. Antidepressants pharmacoeconomic studies. Antidepressants rank in the top three drug classes worldrank in the top three drug classes worldwide in terms of sales dollars. Their growth wide in terms of sales dollars. Their growth in sales ranks them among the top five drug in sales ranks them among the top five drug classes worldwide (IMS Health, 2001) . classes worldwide (IMS Health, 2001 ). Additionally, these antidepressants are the Additionally, these antidepressants are the subject of multiple cost-outcome studies subject of multiple cost-outcome studies reporting quantitative results. reporting quantitative results.
Study sample Study sample
To locate reports of pharmacoeconomic To locate reports of pharmacoeconomic studies of antidepressant drugs we used studies of antidepressant drugs we used the Cochrane Library, Medline and Healththe Cochrane Library, Medline and Health-STAR databases supplemented by manual STAR databases supplemented by manual searches based on the references cited in searches based on the references cited in the studies located through the databases. the studies located through the databases. We searched for all articles between We searched for all articles between 1987 -the year the first 'newer ' antidepres-1987 - (Jonsson & Bebbington, 1993 , 1994 (Jonsson & Bebbington, 1993 , 1994 Hatziandreu Hatziandreu et al et al, 1994; Le Pen , 1994; Le Pen et al et al, , 1994; McFarland, 1994; Sclar 1994; McFarland, 1994; Sclar et al et al, 1994 Sclar et al et al, , , 1994 Sclar et al et al, , 1995 Sclar et al et al, , 1998 Sclar et al et al, , 1999 Stewart, 1994; Anton 1995 Anton , 1998 Anton , 1999 Stewart, 1994; Anton & Revicki, 1995; Einarson & Revicki, 1995; Einarson et al et al, 1995 Einarson et al et al, , , 1995 Einarson et al et al, , 1997 Lapierre 1997; Lapierre et al et al, 1995; Nuijten , 1995; Nuijten et al et al, , 1995; Revicki 1995; Revicki et al et al, 1995 Revicki et al et al, , 1997 Skaer , 1995 Skaer , , 1997 Skaer et et al al, 1995; Bentkover & Feighner, 1996; , 1995; Bentkover & Feighner, 1996; Forder Forder et al et al, 1996; Hylan , 1996; Hylan et al et al, 1996 Hylan et al et al, , , 1996 Hylan et al et al, , 1998 Montgomery 1998; Montgomery et al et al, 1996; Smith & , 1996; Smith & Sherrill, 1996; Croghan Sherrill, 1996; Croghan et al et al, 1997 Croghan et al et al, , 2000 , 1997 , 2000 Melton Melton et al et al, 1997; Obenchain , 1997; Obenchain et al et al, , 1997; Woods & Rizzo, 1997; Boyer 1997; Woods & Rizzo, 1997; Boyer et al et al, , 1998; Canadian Coordinating Office for 1998; Canadian Coordinating Office for Health Technology Assessment, 1998; Health Technology Assessment, 1998; Crown Crown et al et al, 1998; Simon & Fishman, , 1998; Simon & Fishman, 1998; Thompson 1998; Thompson et al et al, 1998; Brown , 1998; Brown et al et al, , 1999 Brown et al et al, , 1999a Griffiths ; Griffiths et al et al, 1999; Nurnberg , 1999; Nurnberg et al et al, 1999; Russell , 1999; Russell et al et al, 1999; Simon , 1999; Simon et al et al, 1999; Borghi & Guest, 2000; Sullivan , 1999; Borghi & Guest, 2000; Sullivan et al et al, 2000; Casciano , 2000; Casciano et al et al, 2001; Doyle , 2001; Doyle et et al al, 2001; Poret , 2001; Poret et al et al, 2001; Wan , 2001; Wan et al et al, , 2002) . We excluded two studies (Boyer 2002) . We excluded two studies (Boyer et et al al, 1998; Simon , 1998; Simon et al et al, 1999) because they , 1999) because they were randomised trials, unlike all the other were randomised trials, unlike all the other studies, which were modelling studies or studies, which were modelling studies or analyses of administrative databases. The analyses of administrative databases. The remaining articles represent 45 separate remaining articles represent 45 separate studies. Two articles report the results of studies. Two articles report the results of one study (Jonsson & Bebbington, 1993 , one study (Jonsson & Bebbington, 1993 , 1994 . Two articles report two studies 1994). Two articles report two studies each, one in-patient, one out-patient each, one in-patient, one out-patient (Einarson (Einarson et al et al, 1995 (Einarson et al et al, , 1997 . Two articles , 1995 Two articles , , 1997 . Two articles reported slight variations on two studies, reported slight variations on two studies, one in-patient and one out-patient (Casciaone in-patient and one out-patient (Casciano no et al et al, 2001; Doyle , 2001; Doyle et al et al, 2001) . , 2001).
Classification of studies Classification of studies
For the primary analysis we categorised For the primary analysis we categorised each study according to whether it was each study according to whether it was industry-sponsored. The study was cateindustry-sponsored. The study was categorised as industry-sponsored if at least gorised as industry-sponsored if at least one author was listed as a pharmaceutical one author was listed as a pharmaceutical company employee, or an acknowledgecompany employee, or an acknowledgement listed pharmaceutical company ment listed pharmaceutical company support; otherwise, it was categorised as support; otherwise, it was categorised as non-industry-sponsored. For secondary non-industry-sponsored. For secondary analyses we categorised studies authored analyses we categorised studies authored by industry employees separately from by industry employees separately from studies only listing financial support. studies only listing financial support. Study sponsors were categorised by Study sponsors were categorised by product into those manufacturing selective product into those manufacturing selective serotonin reuptake inhibitors (SSRIs: fluoxserotonin reuptake inhibitors (SSRIs: fluoxetine, sertraline, paroxetine and citaloetine, sertraline, paroxetine and citalopram) or 'atypical' antidepressant drugs pram) or 'atypical' antidepressant drugs (venlafaxine, bupropion and mirtazapine). (venlafaxine, bupropion and mirtazapine).
Operationalisation of outcomes Operationalisation of outcomes
For either of the questions posed in our For either of the questions posed in our study no single means of operationalising study no single means of operationalising the issue of which antidepressant was the issue of which antidepressant was favoured could be applied to all studies. favoured could be applied to all studies. Therefore, we performed separate analyses Therefore, we performed separate analyses using alternative operationalisations. using alternative operationalisations. Specifically, for question one (the industry Specifically, for question one (the industry v. v. non-industry comparison), no single non-industry comparison), no single standard was applicable that allowed standard was applicable that allowed analysis of all 46 studies. Seemingly simple analysis of all 46 studies. Seemingly simple standards such as 'sponsor's antidepressant standards such as 'sponsor's antidepressant favoured' could not apply: in nonfavoured' could not apply: in nonindustryindustry-sponsored studies, there is no sponsored studies, there is no 'sponsor's 'sponsor's anti antidepressant'. In our primary depressant'. In our primary analysis of industry-sponsored analysis of industry-sponsored v.
v. nonnonindustryindustry-sponsored studies we examined sponsored studies we examined whether the outcome favoured SSRIs or whether the outcome favoured SSRIs or tricyclic antidepressants (TCAs), excluding tricyclic antidepressants (TCAs), excluding studies sponsored by 'atypical' antidepressant studies sponsored by 'atypical' antidepressant manufacturers. To allow analysis of the latter manufacturers. To allow analysis of the latter studies, we performed an alternative analysis studies, we performed an alternative analysis based on whether the outcome favoured the based on whether the outcome favoured the 'newest antidepressant' ('newness' was based 'newest antidepressant' ('newness' was based upon date of FDA approval). In this analysis, upon date of FDA approval). In this analysis, studies in which the sponsor's drug was not studies in which the sponsor's drug was not the newest were excluded. the newest were excluded.
In addressing our second question, In addressing our second question, regarding the association of study design regarding the association of study design with bias on outcome, we examined the with bias on outcome, we examined the issue both within industry-sponsored trials issue both within industry-sponsored trials and between industry-sponsored and nonand between industry-sponsored and nonindustry-sponsored trials. Within the first industry-sponsored trials. Within the first group we looked at the association of group we looked at the association of modelling modelling v.
v. administrative study designs administrative study designs with outcome. We operationalised the outwith outcome. We operationalised the outcomes and groups in two alternative ways: comes and groups in two alternative ways: favouring the newest drug among all favouring the newest drug among all industry-sponsored studies, or favouring industry-sponsored studies, or favouring the sponsored drug among all industrythe sponsored drug among all industrysponsored studies. sponsored studies.
In examining the association of study In examining the association of study design with outcome between industry design with outcome between industry v.
v. non-industry sponsors, we compared the non-industry sponsors, we compared the outcome patterns within modelling studies. outcome patterns within modelling studies. We could not compare outcome patterns in We could not compare outcome patterns in administrative data studies given there was administrative data studies given there was only one such non-industry-sponsored only one such non-industry-sponsored study. We operationalised outcomes in study. We operationalised outcomes in two alternative ways: favouring the newest two alternative ways: favouring the newest drug, or favouring SSRIs drug, or favouring SSRIs v.
v. TCAs. TCAs.
Rating study outcomes Rating study outcomes Most studies contained several outMost studies contained several outcomes. However, we wished to rate a single comes. However, we wished to rate a single outcome from each study and employed the outcome from each study and employed the following decision rules to select that outfollowing decision rules to select that outcome. First, we selected only quantitative come. First, we selected only quantitative outcomes. Second, among base case and outcomes. Second, among base case and variants, we selected the base case. Third, variants, we selected the base case. Third, among outcomes adjusted for bias and among outcomes adjusted for bias and unadjusted outcomes, we selected the unadjusted outcomes, we selected the adjusted outcome. Fourth, among outadjusted outcome. Fourth, among outcomes for various time periods, we selected comes for various time periods, we selected the longest period. Fifth, among multiple the longest period. Fifth, among multiple pharmacoeconomic indicators, we selected pharmacoeconomic indicators, we selected a single outcome on the basis of the followa single outcome on the basis of the following rules: if only cost outcomes were ing rules: if only cost outcomes were reported, we chose total costs over more reported, we chose total costs over more limited costs; if cost and cost-effectiveness limited costs; if cost and cost-effectiveness outcomes were reported, we chose costoutcomes were reported, we chose costeffectiveness outcomes; and if more than effectiveness outcomes; and if more than one type of cost-effectiveness ratio was reone type of cost-effectiveness ratio was reported, we chose incremental over average ported, we chose incremental over average ratios. Sixth, if results were reported separatios. Sixth, if results were reported separately for individual countries, we selected rately for individual countries, we selected the results for the UK and the USA. the results for the UK and the USA.
After selecting a single outcome for After selecting a single outcome for each study, the researchers rated each study each study, the researchers rated each study as favourable, neutral or unfavourable for as favourable, neutral or unfavourable for the drug of interest, depending on the the drug of interest, depending on the particular analysis (e.g. SSRI in the SSRI particular analysis (e.g. SSRI in the SSRI v. v. TCA analysis, or newest antidepressant TCA analysis, or newest antidepressant in the newest in the newest v.
v. older antidepressant older antidepressant analysis): 'favourable' meant that a drug's analysis): 'favourable' meant that a drug's quantitative cost-effectiveness results were quantitative cost-effectiveness results were unequalled by any of the other drugs in unequalled by any of the other drugs in the study; 'neutral' meant that although the study; 'neutral' meant that although other drugs' results might be equal to it, other drugs' results might be equal to it, none surpassed the drug of interest; and none surpassed the drug of interest; and 'unfavourable' meant that other drugs' 'unfavourable' meant that other drugs' results did surpass the drug of interest. results did surpass the drug of interest.
Raters used all available information to Raters used all available information to judge differences in outcomes among drugs. judge differences in outcomes among drugs. If the study reported statistical significance, If the study reported statistical significance, raters based their judgements on statistically raters based their judgements on statistically significant differences. If the study did not significant differences. If the study did not report statistical significance, raters based report statistical significance, raters based their judgements on the reported numerical their judgements on the reported numerical differences. With quality-adjusted life-years differences. With quality-adjusted life-years (QALYs), raters judged a treatment super-(QALYs), raters judged a treatment superior if marginal cost-effectiveness was less ior if marginal cost-effectiveness was less than US$20 000 per QALY, a common than US$20 000 per QALY, a common applied limit (Laupacis applied limit (Laupacis et al et al, 1992) . Sub-, 1992) . Subsequently, we performed a sensitivity analysequently, we performed a sensitivity analysis by varying the marginal threshold sis by varying the marginal threshold between $20 000 and $100 000 per QALY. between $20 000 and $100 000 per QALY.
The following is an example of how The following is an example of how raters applied the rules noted above to raters applied the rules noted above to designate a specific study as favourable, designate a specific study as favourable, neutral or unfavourable. In the SSRI neutral or unfavourable. In the SSRI v.
v. tritricyclic or heterocyclic antidepressant analycyclic or heterocyclic antidepressant analysis of the Hatziandreu study (Hatziandreu sis of the Hatziandreu study (Hatziandreu et al et al, 1994 ) the preceding rules led raters , 1994) the preceding rules led raters to judge that the study favoured the SSRI. to judge that the study favoured the SSRI. The study reported the base case increThe study reported the base case incremental cost-effectiveness ratio to be £2172 mental cost-effectiveness ratio to be £2172 ($3692) for each QALY gained by using ($3692) for each QALY gained by using the SSRI rather than the TCA. This cost the SSRI rather than the TCA. This cost per QALY gained is less than the $20 000 per QALY gained is less than the $20 000 per QALY cut-off noted in the raters' deciper QALY cut-off noted in the raters' decision rules; therefore, the study was rated as sion rules; therefore, the study was rated as favourable for the SSRI. favourable for the SSRI.
In addition to the planned analyses In addition to the planned analyses described above, we performed two described above, we performed two exploratory analyses: one was based on exploratory analyses: one was based on the number of industry authors and the the number of industry authors and the second was based on the ordinal position second was based on the ordinal position of any industry authors. Neither of these of any industry authors. Neither of these analyses yielded a significant association. analyses yielded a significant association.
We analysed the association between We analysed the association between sponsorship and outcome using Fisher's sponsorship and outcome using Fisher's exact test as generalised for 2 exact test as generalised for 26 63 3 tables. We chose contingency table analysis tables. We chose contingency table analysis rather than a meta-analytic technique rather than a meta-analytic technique because of the qualitative heterogeneity of because of the qualitative heterogeneity of the pharmacoeconomic outcome types the pharmacoeconomic outcome types across studies, which ranged from direct across studies, which ranged from direct costs per patient, to direct costs per treatcosts per patient, to direct costs per treatment success, to direct costs per symptomment success, to direct costs per symptomfree day, to lifetime direct costs per free day, to lifetime direct costs per discounted QALY. We judged it discounted QALY. We judged it inappropriate to transform these qualitainappropriate to transform these qualitatively disparate types of outcomes into a tively disparate types of outcomes into a common effect size. We selected the 0.05 common effect size. We selected the 0.05 a a level, two-tailed.
level, two-tailed.
RESULTS RESULTS
Details of the studies are listed in Tables  Details of the studies are listed in Tables 1-3 . 1-3. v. TCA TCA studies, six of seven non-industry-sponsored studies, six of seven non-industry-sponsored studies were eligible for analysis (see Table  studies were eligible for analysis (see Table  3 ). Seventeen industry studies were eligible 3). Seventeen industry studies were eligible (see Tables 1 and 2) . (see Tables 1 and 2 ).
Distribution and results for Fisher's Distribution and results for Fisher's exact test are noted in Table 4 . The associaexact test are noted in Table 4 . The association between industry sponsorship and tion between industry sponsorship and outcome favouring SSRIs outcome favouring SSRIs v.
v. TCAs was TCAs was statistically significant. Each of the two statistically significant. Each of the two secondary analyses contrasting studies with secondary analyses contrasting studies with industry-employed authors industry-employed authors v.
v. non-industrynon-industrysponsored studies and contrasting studies sponsored studies and contrasting studies with industry funding alone with industry funding alone v.
v. non-industrynon-industrysponsored studies demonstrated a statistisponsored studies demonstrated a statistically significant association between industry cally significant association between industry sponsorship and outcome favouring SSRIs sponsorship and outcome favouring SSRIs v.
v. TCAs, with probability values of 0.0420 and TCAs, with probability values of 0.0420 and 0.0163 respectively. 0.0163 respectively.
New v. old antidepressant analysis New v. old antidepressant analysis
All non-industry-sponsored studies were All non-industry-sponsored studies were eligible (see Table 3 ). Thirty-three industryeligible (see Table 3 ). Thirty-three industrysponsored studies (see Tables 1 and 2) were sponsored studies (see Tables 1 and 2) Association between study design Association between study design and sponsorship bias and sponsorship bias
Question 1 Question 1
Within industry-sponsored studies, is there Within industry-sponsored studies, is there a difference in tendency to favour the a difference in tendency to favour the sponsor's drug over a competitor's drug or sponsor's drug over a competitor's drug or drug class, based on type of study design? drug class, based on type of study design? For the principal analysis, 'favouring the For the principal analysis, 'favouring the 5 0 2 5 0 2 sponsor's drug or drug class' was defined sponsor's drug or drug class' was defined based on favouring the newest drug among based on favouring the newest drug among all manufacturer-sponsored studies. Thirtyall manufacturer-sponsored studies. Thirtythree industry-sponsored studies were three industry-sponsored studies were eligible (see Tables 1 and 2 ). Distribution eligible (see Tables 1 and 2 ). Distribution and results of the Fisher's exact test are and results of the Fisher's exact test are noted in Table 4 . The association between noted in Table 4 . The association between modelling modelling v. v. administrative study design administrative study design and outcome favouring the newest drug and outcome favouring the newest drug was statistically significant. was statistically significant.
For our alternative analysis based on For our alternative analysis based on whether the sponsor's drug or drug class whether the sponsor's drug or drug class won, regardless of whether it was newest, won, regardless of whether it was newest, all 38 industry-sponsored studies were all 38 industry-sponsored studies were eligible (see Tables 1 and 2 ). This analysis eligible (see Tables 1 and 2 ). This analysis yielded a probability value of 0.0011, yielded a probability value of 0.0011, consistent with the results in the primary consistent with the results in the primary analysis. analysis.
Question 2 Question 2
Between industry-sponsored and nonBetween industry-sponsored and nonindustry-sponsored modelling design industry-sponsored modelling design studies, is there a difference in outcome studies, is there a difference in outcome patterns? For the principal analysis of this patterns? For the principal analysis of this question we examined the patterns of question we examined the patterns of favouring the newest drug. Nineteen indusfavouring the newest drug. Nineteen industry studies (see Tables 1 and 2 ) and five try studies (see Tables 1 and 2 ) and five non-industry studies (see Table 3 ) were non-industry studies (see Table 3 ) were eligible. The distribution and results of the eligible. The distribution and results of the Fisher's exact test are noted in Table 4 . Fisher's exact test are noted in Table 4 . The association between industry The association between industry v.
v. nonnonindustry sponsorship of modelling studies industry sponsorship of modelling studies and outcome favouring the newest drug and outcome favouring the newest drug was statistically significant. Each of the was statistically significant. Each of the two secondary analyses contrasting studies two secondary analyses contrasting studies with industry-employed authors with industry-employed authors v.
v. nonnonindustry-sponsored studies and contrasting industry-sponsored studies and contrasting studies with industry funding alone studies with industry funding alone v.
v. non-industry-sponsored studies demonnon-industry-sponsored studies demonstrated a statistically significant association strated a statistically significant association between industry sponsorship and outcome between industry sponsorship and outcome favouring the newest antidepressant in favouring the newest antidepressant in modelling studies, with probability values modelling studies, with probability values of 0.0010 and 0.0100 respectively. of 0.0010 and 0.0100 respectively.
In an alternative analysis we examined In an alternative analysis we examined the patterns of favouring SSRIs the patterns of favouring SSRIs v.
v. favouring favouring TCAs in modelling studies. We performed TCAs in modelling studies. We performed this analysis with the five eligible nonthis analysis with the five eligible nonindustry-sponsored studies (see Table 3 ) industry-sponsored studies (see Table 3 ) contrasted first with all twelve eligible contrasted first with all twelve eligible industry-sponsored modelling studies (see industry-sponsored modelling studies (see Tables 1 and 2 ) that included SSRI Tables 1 and 2 ) that included SSRI v v. . TCA comparisons, and then with the six TCA comparisons, and then with the six eligible modelling studies sponsored by eligible modelling studies sponsored by SSRI manufacturers (see Table 1 ) that SSRI manufacturers (see Table 1 ) that included SSRI included SSRI v.
v. TCA comparisons. The TCA comparisons. The results of the Fisher's exact test in the two results of the Fisher's exact test in the two cases were 0.0139 and 0.0151 respectively, cases were 0.0139 and 0.0151 respectively, indicating that the tendency for industryindicating that the tendency for industrysponsored simulations to favour SSRIs sponsored simulations to favour SSRIs more often than non-industry-sponsored more often than non-industry-sponsored studies is unlikely to be due to chance. studies is unlikely to be due to chance.
The sensitivity analysis varying the The sensitivity analysis varying the marginal cost-effectiveness threshold from marginal cost-effectiveness threshold from $20 000 to $100 000 per QALY did not $20 000 to $100 000 per QALY did not change any of the results reported above. change any of the results reported above.
DISCUSSION DISCUSSION
Our analyses show that, regardless of how Our analyses show that, regardless of how the question was operationalised, for each the question was operationalised, for each of our study questions there was greater of our study questions there was greater than chance association between study than chance association between study sponsorship and outcome. Among industrysponsorship and outcome. Among industrysponsored sponsored v.
v. non-industry-sponsored studies, non-industry-sponsored studies, industry-sponsored studies more frequently industry-sponsored studies more frequently reported results reported results favourable to the industry favourable to the industry sponsor than did nonsponsor than did non-industry-sponsored industry-sponsored studies. This was true whether industry studies. This was true whether industry sponsorship was defined as industry sponsorship was defined as industry authorship, industry financial support authorship, industry financial support alone, or both. Among industry studies, alone, or both. Among industry studies, modelling studies were more likely to modelling studies were more likely to report results favourable to the sponsor report results favourable to the sponsor than administrative data studies. Between than administrative data studies. Between industry-sponsored and non-industryindustry-sponsored and non-industrysponsored modelling design studies, sponsored modelling design studies, industry studies were more likely to report industry studies were more likely to report results favourable to industry. results favourable to industry.
Consistency with prior studies Consistency with prior studies
Our overall finding of sponsorship bias is Our overall finding of sponsorship bias is consistent with prior studies in that all consistent with prior studies in that all three prior fully reported studies found three prior fully reported studies found some association between study sponsorsome association between study sponsorship and outcomes (Azimi & Welch, ship and outcomes (Azimi & Welch, 1998; Friedberg 1998; Friedberg et al et al, 1999; Neumann , 1999; Neumann et et al al, 2000 , 2000a a). However, any detailed compar-). However, any detailed comparison between our study and previous ison between our study and previous studies is necessarily limited given that the studies is necessarily limited given that the previous studies mixed drugs, devices and previous studies mixed drugs, devices and other health interventions, and mixed other health interventions, and mixed various classes of medicines (Azimi & various classes of medicines (Azimi & Welch, 1998; Neumann Welch, 1998; Neumann et al et al, 2000 , 2000a a); ); focused on qualitative conclusions (Friedfocused on qualitative conclusions (Friedberg berg et al et al, 1999); and used various defini-, 1999); and used various definitions to select the specific study outcomes tions to select the specific study outcomes to be analysed (Azimi & Welch, 1998 ; to be analysed (Azimi & Welch, 1998; Friedberg Friedberg et al et al, 1999; Neumann , 1999; Neumann et al et al, , 2000 Neumann et al et al, , 2000a . The study by Friedberg ). The study by Friedberg et al et al (1999) of oncology drugs is perhaps most (1999) of oncology drugs is perhaps most comparable with our current study, given comparable with our current study, given their focus on a single pharmaceutical class their focus on a single pharmaceutical class and their categorisation of study concluand their categorisation of study conclusions as favourable, neutral or unfavoursions as favourable, neutral or unfavourable, although they focused on qualitative able, although they focused on qualitative rather than quantitative conclusions. Like rather than quantitative conclusions. Like our study, that of Friedberg our study, that of Friedberg et al et al did find did find an association between study conclusion an association between study conclusion and funding source. and funding source.
Support for concern Support for concern about modelling studies about modelling studies
In addition to supporting the general In addition to supporting the general concern about sponsorship bias in pharmaco concern about sponsorship bias in pharmaco--economic studies, our findings support the economic studies, our findings support the more specific concerns that have been more specific concerns that have been raised about the potential for bias in modelraised about the potential for bias in modelling studies (Luce, 1995; O'Brien, 1996; ling studies (Luce, 1995; O'Brien, 1996; Sheldon, 1996; Maynard & Cookson, Sheldon, 1996; Maynard & Cookson, 1998; McCabe & Dixon, 2000) . Such 1998; McCabe & Dixon, 2000) . Such support stems from the combination of support stems from the combination of our two findings regarding study design: our two findings regarding study design: among industry studies, modelling studies among industry studies, modelling studies are more favourable to the sponsor than are more favourable to the sponsor than administrative studies, and in a comparison administrative studies, and in a comparison of industry-sponsored and non-industryof industry-sponsored and non-industrysponsored modelling studies, studies sponsored modelling studies, studies sponsored by industry are significantly sponsored by industry are significantly more favourable to industry. more favourable to industry.
Limitations of our study Limitations of our study
Our study has clear limitations. RandomOur study has clear limitations. Randomised pharmacoeconomic trials could not ised pharmacoeconomic trials could not be compared on the basis of sponsorship be compared on the basis of sponsorship because there were only two such trials because there were only two such trials in this area. Relatively few non-industryin this area. Relatively few non-industrysponsored studies were available. We sponsored studies were available. We examined only one class of medications; examined only one class of medications; analyses of other classes of medications analyses of other classes of medications should be conducted. should be conducted.
Bias Bias v. v. accuracy accuracy
Although we have demonstrated several Although we have demonstrated several associations between study sponsorship associations between study sponsorship and outcome, these associations do not and outcome, these associations do not suggest which (if either) side presents a suggest which (if either) side presents a more accurate estimate of relative pharmaco more accurate estimate of relative pharmaco--economic outcome. Both industryeconomic outcome. Both industrysupported and non-industry-supported resupported and non-industry-supported researchers may be subject to forces that searchers may be subject to forces that could potentially bias their work (Yee & could potentially bias their work (Yee & Hillman, 1997; Drummond, 1998; Rennie Hillman, 1997; Drummond, 1998; Rennie & Luft, 2000) . Additionally, journal editor-& Luft, 2000). Additionally, journal editorial processes can result in a biased sample ial processes can result in a biased sample of studies being published. It has been of studies being published. It has been observed that journals tend to publish observed that journals tend to publish studies with 'positive' rather than 'negative' studies with 'positive' rather than 'negative' results (Freemantle & Mason, 1997) . results (Freemantle & Mason, 1997) .
Causes of bias Causes of bias
Many ideas have been offered to explain Many ideas have been offered to explain how sponsorship could result in biased how sponsorship could result in biased reported outcomes (Udrarhelyi reported outcomes (Udrarhelyi et al et al, 1992; , 1992; Freemantle & Mason, 1997; Drummond, Freemantle & Mason, 1997; Drummond, 1998; Cook, 1999; Neumann 1998; Cook, 1999; Neumann et al et al, , 5 0 3 5 0 3 Rennie & Luft, 2000) . Industry, ; Rennie & Luft, 2000) . Industry, motivated to enhance sales of its products, motivated to enhance sales of its products, might only pursue studies on products and might only pursue studies on products and select comparators that would yield select comparators that would yield favourable results. They might select favourable results. They might select biased populations within administrative biased populations within administrative data-sets, overtly or subtly influence data-sets, overtly or subtly influence analyanalytical methods or models, or veto subtical methods or models, or veto submission for publication of studies yielding mission for publication of studies yielding unfavourable results. Non-industryunfavourable results. Non-industrysponsored researchers might bias the sponsored researchers might bias the studies submitted for publication in similar studies submitted for publication in similar ways, although perhaps from different ways, although perhaps from different motivations such as controlling formulary motivations such as controlling formulary costs, personal or academic rivalries, or costs, personal or academic rivalries, or career promotion. career promotion.
We are unable to pinpoint the causes of We are unable to pinpoint the causes of bias among the reports analysed here. bias among the reports analysed here. Examination of the individual studies Examination of the individual studies does not reveal a common element that does not reveal a common element that differ differentiates industry-sponsored from entiates industry-sponsored from nonnon-industry-sponsored studies; rather, the industry-sponsored studies; rather, the methodological limitations in the studies methodological limitations in the studies vary widely. These limitations have been vary widely. These limitations have been discussed extensively elsewhere (Hotopf discussed extensively elsewhere (Hotopf et al et al, 1996; Woods & Baker, 1997 , , 1996 Woods & Baker, 1997 , 2002 . However, at least two suggested 2002). However, at least two suggested causes seem unlikely. First, some commencauses seem unlikely. First, some commentators have noted the potential role of selectators have noted the potential role of selection bias -i.e. the tendency of researchers tion bias -i.e. the tendency of researchers not to submit and of journals not to publish not to submit and of journals not to publish small studies or studies with negative statissmall studies or studies with negative statistical outcomes (Freemantle & Mason, tical outcomes (Freemantle & Mason, 1997; Neumann, 1998) . This would help 1997; Neumann, 1998) . This would help to explain how an overall preponderance to explain how an overall preponderance of statistically positive studies could exist of statistically positive studies could exist even if there were true uncertainty about even if there were true uncertainty about alternative medications (Djulbegovic alternative medications (Djulbegovic et al et al, , 2000) . The difference we have shown 2000). The difference we have shown between industry-sponsored and nonbetween industry-sponsored and nonindustry-sponsored studies suggests that industry-sponsored studies suggests that submission or editorial selection bias based submission or editorial selection bias based on statistical significance alone does not on statistical significance alone does not adequately explain the bias in the present adequately explain the bias in the present case. Second, it has been suggested that a case. Second, it has been suggested that a particular sponsor weeds out weak alternaparticular sponsor weeds out weak alternatives among its drugs in early preliminary tives among its drugs in early preliminary processes; therefore, drugs that reach the processes; therefore, drugs that reach the stage of being marketed are strong competistage of being marketed are strong competitors and likely to yield analyses that favour tors and likely to yield analyses that favour the sponsor's drug (Gagnon, 2000) . the sponsor's drug (Gagnon, 2000) . However, these same strong competitors However, these same strong competitors performed less well in non-industryperformed less well in non-industrysponsored studies, as shown clearly in our sponsored studies, as shown clearly in our analysis of outcomes favouring either SSRIs analysis of outcomes favouring either SSRIs or TCAs. Moreover, it should be noted that or TCAs. Moreover, it should be noted that in the 18 studies with head-to-head comin the 18 studies with head-to-head comparisons among such strong competitors, parisons among such strong competitors, the sponsor's drug lost only once (Einarson the sponsor's drug lost only once (Einarson et al et al, 1995) .
, 1995).
Bias in efficacy
Bias in efficacy v. v. pharmacoeconomic studies pharmacoeconomic studies
It is not possible to comment about whether It is not possible to comment about whether the bias revealed in the current study of the bias revealed in the current study of pharmacoeconomic reports of antipharmacoeconomic reports of antidepressants is any greater or less than the depressants is any greater or less than the sponsorship bias that may exist in efficacy sponsorship bias that may exist in efficacy studies of antidepressants. There is no pubstudies of antidepressants. There is no published report on sponsorship bias in efficacy lished report on sponsorship bias in efficacy studies in any medication category within studies in any medication category within psychiatry. The only published report psychiatry. The only published report devoted to such quantitative analysis of devoted to such quantitative analysis of psychiatric medications is a letter reviewing psychiatric medications is a letter reviewing efficacy studies of any psychiatric mediefficacy studies of any psychiatric medication in one journal over a 1-year period cation in one journal over a 1-year period (Mandelkern, 1999) . This author reported (Mandelkern, 1999) . This author reported a tally for industry-supported studies of a tally for industry-supported studies of 16 favourable to the manufacturer's drug 16 favourable to the manufacturer's drug and none unfavourable, and for unsupand none unfavourable, and for unsupported studies 10 favourable and 6 unfaported studies 10 favourable and 6 unfavourable, concluding that there was a vourable, concluding that there was a correlation between source of support and correlation between source of support and efficacy outcome. In other areas of mediefficacy outcome. In other areas of medicine, bias has been demonstrated repeatedly cine, bias has been demonstrated repeatedly in efficacy studies (Davidson, 1986;  in efficacy studies (Davidson, 1986; Rochon Rochon et al et al, 1994; Stelfox , 1994; Stelfox et al et al, 1998; , 1998; Djulbegovic Djulbegovic et al et al, 2000) . A study of , 2000). A study of sponsorship bias in efficacy trials of sponsorship bias in efficacy trials of antidepressants would provide a useful antidepressants would provide a useful comparison for our study. comparison for our study.
It is important for pharmacoeconomic It is important for pharmacoeconomic studies to attempt to give estimates that studies to attempt to give estimates that are as accurate and uninfluenced by bias are as accurate and uninfluenced by bias as possible, given the large and growing as possible, given the large and growing number of health care dollars spent on number of health care dollars spent on medications. Pharmaceutical sales for medications. Pharmaceutical sales for North America were reported to be North America were reported to be US$153 billion in 2000, representing a US$153 billion in 2000, representing a 14% growth over the previous year (IMS 14% growth over the previous year (IMS Health, 2001 ). Owing to the importance Health, 2001). Owing to the importance of cost constraint in medicine the volume of cost constraint in medicine the volume of pharmacoeconomic research has been of pharmacoeconomic research has been growing (Detsky, 1994) and is linked to growing (Detsky, 1994) and is linked to governmental purchasing decisions in some governmental purchasing decisions in some jurisdictions (Canadian Coordinating jurisdictions (Canadian Coordinating Office for Health Technology Assessment, Office for Health Technology Assessment, 1994; Ontario Ministry of Health, 1994; 1994; Ontario Ministry of Health, 1994; Australian Government, 1995) . However Australian Government, 1995). However as we noted previously, financial and other as we noted previously, financial and other incentives create strong motives for bias. incentives create strong motives for bias. Our results for antidepressants suggest that Our results for antidepressants suggest that actual bias related to sponsorship appears actual bias related to sponsorship appears to exist, although whether or how the bias to exist, although whether or how the bias and specific motives are related cannot be and specific motives are related cannot be determined. Until the mechanisms prodetermined. Until the mechanisms producing the bias are better understood, ducing the bias are better understood, interpretation of results from pharmacointerpretation of results from pharmacoeconomic studies should take sponsorship economic studies should take sponsorship into account. into account. 
